Clinical Trial Update: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer [Phase 2, Phase 3]

View source ↗

Summary

Results from a Phase 2/3 trial evaluating the combination of cediranib and olaparib versus each drug alone or chemotherapy in recurrent platinum-resistant ovari…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Cediranib (Cediranib)
• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-06